相关实验视频

Updated: Jul 21, 2026

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
14:54

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

10.8K

儿科免疫媒介性死性肌肉病:一个单一中心的回顾性队列研究

Yikang Wang1, Mengting Yang1, Yawen Zhao1

  • 1Department of Neurology, Peking University First Hospital, Beijing, China.

Pediatric neurology
|April 9, 2025
PubMed
概括

儿科免疫媒介性死性肌肉病 (IMNM) 经常与抗-3-基-3-甲基氨酸-CoA减少酶 (anti-HMGCR) 抗体相关,并呈现出慢性发病和近位弱点. 这些患者往往对免疫抑制疗法反应不佳.

关键词:
抗HMGCR肌肉病变的治疗方法抗SRP肌肉病变的治疗方法磁共振成像技术 磁共振成像技术肌肉活检 肌肉活检肌肉炎特异性抗体 肌肉炎特异性抗体儿科免疫媒介性死性肌肉病变.

更多相关视频

A Neonatal BALB/c Mouse Model of Necrotizing Enterocolitis05:39

A Neonatal BALB/c Mouse Model of Necrotizing Enterocolitis

Published on: November 30, 2021

3.5K
Author Spotlight: Enhancing Understanding and Treatment Strategies with the NEC-on-a-Chip Model06:51

Author Spotlight: Enhancing Understanding and Treatment Strategies with the NEC-on-a-Chip Model

Published on: July 28, 2023

1.1K

相关概念视频

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...